Compare ISPC & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ISPC | SCNI |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 4.6M |
| IPO Year | 2021 | N/A |
| Metric | ISPC | SCNI |
|---|---|---|
| Price | $0.37 | $0.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 541.1K | 59.7K |
| Earning Date | 11-17-2025 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $3,352,744.00 | $1,147,000.00 |
| Revenue This Year | $35.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.67 |
| Revenue Growth | N/A | ★ 303.87 |
| 52 Week Low | $0.36 | $0.70 |
| 52 Week High | $3.38 | $6.18 |
| Indicator | ISPC | SCNI |
|---|---|---|
| Relative Strength Index (RSI) | 31.06 | 31.57 |
| Support Level | $0.36 | $0.70 |
| Resistance Level | $0.44 | $0.85 |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 6.47 | 3.33 |
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.